Arena Pharma (ARNA) to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented during a late-breaking session at the American Academy of Dermatology Virtual Meeting Experience taking place April 23 - 25, 2021.

Title: Etrasimod, a novel, oral, selective sphingosine 1-phosphate receptor modulator, improves patient and clinician reported outcomes in adults with moderate-to-severe atopic dermatitis in a randomized, double-blind, placebo-controlled phase 2 study (ADVISE)
Presenter: Dr. Emma Guttman-Yassky
Authors: Emma Guttman-Yassky, Robert Bissonette, Leon Kircik, Dedee Murrell, Andrew Selfridge, Kris Liu, Gurpreet Ahuluwalia, Jonathan Silverberg
Date/Time: Presentation released 10:00 AM ET on Friday, April 23, 2021 with Q&A 3:00-4:00 PM ET on Saturday, April 24, 2021
Session: Late-Breaking Research Session

About Etrasimod

Etrasimod (APD334) is a next generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena and designed for optimized pharmacology and engagement of S1P receptor 1, 4, and 5, which may lead to an improved efficacy and safety profile.

Etrasimod is intended to provide systemic and local effects on specific immune cell types and has the potential to treat multiple immune-mediated inflammatory diseases including ulcerative colitis, Crohn's disease, eosinophilic esophagitis, atopic dermatitis, and alopecia areata.

Etrasimod is an investigational compound that is not approved for any use in any country.

You May Also Be Interested In

• Hepion Pharmaceuticals (HEPA) Winds Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
• Arista Networks (ANET) Announces COO Resignation
• Asbury Automotive Group (ABG) Announces Retirement of Chief Legal Officer